Abstract: The present invention relates to a method for identifying compounds that modulate cholesterol metabolism by detecting enzyme activities involved in the synthesis or catabolism of cholesterol. Said method enables the lethal risk for mammalian cells when the cholesterol level decreases to be avoided, due to the use of genetically modified yeasts, the survival of which is not strictly dependent upon the cholesterol production.

Abstract: A method for quantitatively determining LDL cholesterol, including the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent so as to preferentially react cholestrols in high density- and very low density-cholesterols among lipoproteins, and subsequently determining the amount of cholesterol that reacts thereafter. This method can eliminate the necessity for pretreatments such as centrifugation and electrophoresis, enables the quantitative determination to be conducted in an efficient, simple manner, and can be applied to various automatic analyzers.

Abstract: This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating symptoms associated with a tendinous or musculoskeletal soft tissue injury. Additionally, the invention provides methods for evaluating the risk of developing a tendinous or musculoskeletal soft tissue injury.

Abstract: Methods, apparatus and systems for collecting thin tissue samples for imaging. Thin tissue sections may be cut from tissue samples using a microtome-quality knife. In one example, tissue samples are mounted to a substrate that is rotated such that thin tissue sections are acquired via lathing. Collection of thin tissue sections may be facilitated by a conveyor belt. Thin tissue sections may be mounted to a thin substrate (e.g., by adhering thin tissue sections to a thin substrate via a roller mechanism) that may be imaged, for example, by an electron beam (e.g., in an electron microscope). This tissue sections may be strengthened before cutting via a blockface thinfilm deposition technique and/or a blockface taping technique. An automated reel-to-reel imaging technique may be employed for collected/mounted tissue sections to facilitate random-access imaging of tissue sections and maintaining a comprehensive library including a large volume of samples.

Abstract: A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.

Abstract: The present invention features, in certain aspects, methods of promoting endocytosis of LDL with ?1PI or peptides derived from ?1PI. The present invention also provides methods for decreasing LDL levels in response to ?1PI augmentation therapy. In preferred embodiments, the methods are suitable for a subject who is suffering from a disease or disorder selected from heart disease, atherosclerosis, hypertension, HIV infection, viral infection, bacterial infection, leukemia, a solid tumor, or autoimmune disease.

Abstract: The present invention provides a composition (composition for suppressing re-elevation of cholesterol) that has the effects of suppressing re-elevation of cholesterol in patients with high cholesterol or pre-high cholesterol, and that can therefore be used to suppress re-elevation of cholesterol in those patients. The present invention also provides a composition which, due to the effects described above, can be used to prevent or treat conditions or diseases caused by high cholesterol due to cholesterol re-elevation, specifically hypercholesterolemia, arteriosclerosis and diseases and conditions stemming therefrom. The composition of this invention uses as an active component an edible protein hydrolysate, preferably a globin proteolysate or a peptide consisting of Val-Val-Tyr-Pro.

Abstract: It is an object of the present invention to provide a method for measuring low density lipoprotein cholesterol (LDL-C) in a body fluid, which is able to selectively measure low density lipoprotein cholesterol in a body fluid without using a low density lipoprotein cholesterol-selective surfactant having a risk of generating endocrine-disrupting chemicals. The present invention provides a method for measuring low density lipoprotein cholesterol (LDL-C) in a body fluid, which comprises measuring low density lipoprotein cholesterol (LDL-C) by using (a) cholesterol esterase and (b) cholesterol oxidase or cholesterol dehydrogenase, in the presence of a polyoxyethylene-polyoxypropylene copolymer and a polyglyceryl ether.

Abstract: The present invention provides a novel sensor for the estimation of total cholesterol in human blood serum using molecular imprint of cholesterol. Human blood serum contains 150-250 mg/dl cholesterol. The present invention provides a sensor device and a process for the fabrication of ISFET (Ion Selective Field Effect Transister) coated with molecular imprint of cholesterol on the SiO2+Si3N4 dielectric gate of the said electrode. The molecular imprint of cholesterol (MIPC) anchored in to a silica matrix sensing material is identified as a sensing material which has specific selectivity towards the cholesterol in presence of other organic constituents in human blood serum.

Abstract: The present invention provides a screening method for identifying test agents that modulate cell membrane cholesterol activity. The modulating activity of the test agents may be measured using lytic compounds, which cause cell lysis or increases in cell permeability in response to cell membrane cholesterol levels. The invention further provides therapeutic agents that are identified using the screening method. The therapeutic agents either increase or decrease the cell membrane cholesterol activity, cholesterol concentration and/or both in vivo and/or in vitro.

Abstract: It is intended to provide an assay method whereby the activity of a lipid-modifying enzyme can be conveniently measured over a wide range and a drug capable of controlling a lipid-modifying enzyme with the use of this assay method. The above problem can be solved by, for example, a method of measuring the activity of a lipid-modifying enzyme which comprises the steps of (I) preparing a lipid micelle containing a biotinylated lipid and a substrate for the lipid-modifying enzyme; (II) bringing the lipid micelle prepared in the above step (I) into contact with the lipid-modifying enzyme; and (III) evaluating the activity of the lipid-modifying enzyme by applying an evaluation method using the proximity effect to the product obtained in the above step (II).

Abstract: A method for measuring LDL cholesterol in a sample using a test piece is provided which involves a step of measuring the total cholesterol in the sample; a step of measuring the non-LDL cholesterol in the sample; and a step of subtracting the non-LDL cholesterol value from the total-cholesterol value to obtain the LDL cholesterol level.

Abstract: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.

Abstract: The present invention relates to a method for determining the degree of risk of onset of autism, comprising the step of measuring the triglyceride concentration or the cholesterol concentration in a very low-density lipoprotein fraction of plasma or serum isolated from a subject, or the triglyceride concentration or the cholesterol concentration of plasma or serum. In addition, the present invention provides a kit for determining the degree of risk of onset of autism and a method for screening for a candidate substance for agents for treating autism using a non-human mammal, in which the above described method is utilized.

Abstract: This invention provides a method for separately or simultaneously quantifying cholesterol in a total amount of HDL-C, cholesterol in an HDL subfraction of apoE-containing HDL-C, and cholesterol in an HDL subfraction of apoE-deficient HDL-C. The method comprises enzymatically and separately quantifying cholesterol in apoE-containing HDL and cholesterol in apoE-deficient HDL by adding a surfactant selected from the group consisting of a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of 0.7 to less than 1.3, a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of less than 0.7, and a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of 1.3 or more to a test sample, allowing cholesterol esterase and cholesterol oxidase to react therewith, and quantifying the hydrogen peroxide generated.

Abstract: A process is provided for analyzing a specimen of biological material in any of a number of biochemical or immunological tests for an analyte which involves subjecting the specimen to treatment which develops a color correlating to the amount of analyte in the specimen. According to the invention at least one defined color characteristic selected from hue angle, chroma, saturation and lightness of the developed color is measured and the results of that measurement analyzed to determine the presence or concentration of the analyte in the specimen. Particular applications are to the detection of cancerous or pre-cancerous abnormalities from the analysis of lung mucus, throat mucus, cervical mucus or seminal fluid.

Abstract: A method for quantitatively determining LDL cholesterol, including the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent so as to preferentially react cholestrols in high density- and very low density-cholesterols among lipoproteins, and subsequently determining the amount of cholesterol that reacts thereafter. This method can eliminate the necessity for pretreatments such as centrifugation and electrophoresis, enables the quantitative determination to be conducted in an efficient, simple manner, and can be applied to various automatic analyzers.

Abstract: The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.

Abstract: The present invention is intended to provide a method for simultaneously measuring cholesterol in low density lipoprotein and total cholesterol as test components in blood. Specifically, a method is used for simultaneously measuring cholesterol in low density lipoprotein and total cholesterol in a biological sample, whereby cholesterol in low density lipoprotein and total cholesterol in a biological sample are quantified with a single measurement.

Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.

Abstract: A reagent including a combination of a polyanionic compound and a bivalent cationic compound contains one substance selected from the group consisting of succinic acid, gluconic acid, alanine, glycine, valine, histidine, maltitol, and mannitol or at least one compound of the substance. A dry state of the reagent and deliquescence can be improved.

Abstract: A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.

Abstract: A method for determination of sdLDL-C in a reaction solution containing a surfactant that preferentially inhibits the reaction of sdLDL-C with enzymes for cholesterol measurement such as cholesterol ester hydrolase. In the method, the enzymes for cholesterol measurement act on a sample to eliminate HDL-C, VLDL-C, CM-C and LgLDL-C. A reagent that causes the reaction of sdLDL-C remaining in the reaction solution to form hydrogen peroxide or reduced coenzyme is then added, following which the formed hydrogen peroxide or reduced coenzyme is measured. The sdLDL-C concentration in the sample may be determined by comparing the measurement value with and a previously-prepared calibration curve.

Abstract: Embodiments of the present invention provide for detecting and/or screening for conditions associated with altered sterols by derivatization of sterols to provide suitable sensitivity and selectivity of detection using tandem mass spectrometry with electrospray ionization. Such testing may be performed to detect and/or screen for conditions such as Smith-Lemli-Opitz syndrome, familial hypercholesterolaemia, and cerebrotendinous xanthomatosis, or certain bile acid disorders.

Abstract: It is an object of the present invention to provide the method for determining cholesterol in lipoprotein and reagent for determining cholesterol comprising the polymer, and the present invention relates to the reagent for determining cholesterol in lipoproteins such as high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) and the determination method using the polymer comprising the following units as constituents: (iv) a polyethylene glycol segment represented by the general formula [1]: —(CH2CH2O)k—??[1] (wherein, k represents an integer of 10 to 250); (v) a monomer unit represented by the general formula [2]: (wherein R1 represents a hydrogen atom or C1-C3 alkyl group); and (vi) a monomer unit represented by the general formula [3]: [wherein, R2 represents a hydrogen atom or C1-C3 alkyl group, and R3 represents a group represented by the general formula [4]: —COOR4??[4] (wherein, R4 represents an alkyl group, a haloalkyl group or a bornyl gro

Abstract: The present invention provides human, rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.

Abstract: The present invention concerns the application of lipidomics to statin treatment for disorders such as cardiovascular disorders. Hence, the invention provides, among other things, a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject following commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The invention further provides a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject before commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen.

Abstract: A biological material fixed region enclosing tip, a biological material fixed region treatment apparatus, and a treatment method thereof. An object is to enable processing to be performed while a fixing region is enclosed in an immovable state with respect to the tip form vessel, and to execute processing of high reliability with a simple apparatus.

Abstract: The present invention provides a method and apparatus for non-invasive measurement of skin cholesterol. More particularly, one aspect of the invention provides for a device to apply a detector reagent to a selected area of skin. Another aspect of the invention provides for an indicator device to produce a visual change corresponding to the amount of detector reagent that is bound in the skin. The method and apparatus of this invention typically do not require any instrumentation for certain embodiments, allowing the invention to be suitable for self-testing, for example, but not limited to, in the home environment. As such the invention is particularly useful to allow individuals to assess their risk of atherosclerosis and related vascular diseases.

Abstract: The present invention provides a method, a reagent and a kit for simple and sensitive determination of cholesterol in remnant-like particles without separation of components of a sample. A method for quantitatively determining remnant-like particle cholesterol in a sample, which comprises: in an aqueous medium containing the sample and in the presence of a combination of specific surfactants and a phospholipid-hydrolyzing enzyme, allowing remnant-like particle cholesterol in the sample to react with cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase (in the presence of oxidized coenzyme); and determining the formed hydrogen peroxide or reduced coenzyme.

Abstract: A biosensor system can comprise a sensor chip and a measurement device. The sensor chip comprises a capillary and electrodes disposed within the capillary. The height of the capillary is set to be less than the maximum value of the sum of the diffusion distance of an electron-transfer mediator and the diffusion distance of an analyte at the upper limit of the measurement guaranteed temperature of the biosensor system. The measurement device applies an open circuit voltage, a voltage that is lower than during concentration measurement, or the like to the electrodes of the sensor chip.

Abstract: A method for determining a concentration of an analyte is disclosed. The method includes applying a potential excitation to a fluid sample containing an analyte and determining if a current decay curve associated with the fluid sample has entered an analyte depletion stage. The method also includes measuring a plurality of current values associated with the fluid sample during the analyte depletion stage and calculating an analyte concentration based on at least one of the plurality of current values.

Abstract: A biosensor manufacturing method including a sheet material forming process and a dicing process. In the sheet material forming process a sheet material with plural biosensor forming sections is formed. Each of the biosensor forming sections includes a first base plate, a second base plate stacked on the first base plate and forming a capillary between the second base plate and the leading end portion of the first base plate for sucking in sample liquid, and a hydrophilic layer formed on the second base plate at least in a region facing the capillary. In the dicing process plural biosensors are obtained by dicing the sheet material with a blade from the first base plate side at the leading end of each of the biosensor forming sections, such that the leading end of the capillary opens onto the leading end face of the first base plate and the second base plate.

Abstract: An object of the present invention is to provide an excellent method for detection and diagnosis of familial combined hyperlipidemia. The present invention relates to a method for detection of familial combined hyperlipidemia by measuring the concentration of small, dense LDL cholesterol in a sample collected from a subject.

Abstract: The present invention relates to the use of surfaces that exhibit different surface energies wherein the difference in surface energies is configured to disrupt capillary laminar flow of a fluid travelling between the two surfaces The invention further relates to the use of such surfaces in assay methods including a device utilising same

Abstract: The invention is directed to a novel enzymatic analytical membrane, a lateral flow enzymatic detection method, and analytical device incorporating same. The invention is useful for rapidly enzymatically determining the presence of one or more analytes in small volumes of sample. The invention provides an enzymatic analytical membrane for detecting the presence of one or more small-molecule analytes in a biological sample where the membrane comprises a receiving zone; a separation zone and a signal zone, at least one of the zones comprising one or more enzymes for converting the analytes into a form detectable by reaction with a chromogenic agent present in the signal zone and wherein the membrane horizontally receives sample at the receiving zone, and the sample continues via lateral flow through the receiving zone, separation zone and signal zone where a visible color change is formed indicating the presence of the analyte.

Abstract: A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability.

Abstract: A test strip or electrochemical sensor for measuring the amount of an analyte in a biological fluid, e.g. the glucose content of whole blood, includes a size self-limiting reagent formulation employing an enzyme system for reaction with the analyte, the reactive system mixed into a water-soluble swellable polymer matrix containing small water-insoluble particles having a nominal size of about 0.05 to 20 ?m, preferably about 1 to 10 ?m. The weight ratio of the water-insoluble particles to the water-soluble swellable polymer matrix is about 1/2 to 2/1. The reagent formulation is deposited onto a non-porous substrate to form a thin layer about 6-16 ?m thick, providing a rapid and stable response to application of a sample, while being insensitive to the amount of the sample.

Abstract: The present invention provides methods that are useful for the diagnosis of neurodegenerative disease or disorder and for the screening of compounds or therapeutic agents for treating a neurodegenerative disease or disorder. The methods pertain in part to the correlation of a neurodegenerative disease or disorder with abnormal or altered endoplasmic reticulum-mitochondrial-associated membranes (ER-MAM) integrity.

Abstract: A reagent for fractional measurement of small, dense LDLs without pretreatment of a specimen, which is adaptable to a rapid and convenient autoanalyzer, is provided. A method for quantitatively determining cholesterol in small, dense LDLs in a sample is further provided. The method includes first step of eliminating lipoproteins other than small, dense LDLs in a sample in the presence of cholesterol esterase and 0.05 g/L to 1.0 g/L of a surfactant that acts on the lipoproteins other than small, dense LDLs, and a second step of quantitatively determining cholesterol in small dense LDLs that remain after the first step.

Abstract: A method for measuring cholesterol in low-density lipoprotein contained in a sample, which comprises reacting a sample with (i) a combination of cholesterol ester hydrolase and cholesterol oxidase or (ii) a combination of cholesterol ester hydrolase, an oxidized coenzyme and cholesterol dehydrogenase in the presence of: [a] a polyoxyethylene-polyoxyalkylene alkylaryl ether; [b] one or more surfactants selected from the group consisting of a polyoxyethylene-polyoxyalkylene copolymer, a polyoxyethylene alkenyl ether, a polyoxyethylene branched alkyl ether, and a polyoxyethylene-polyoxyalkylene branched alkyl ether; [c] one or more surfactants selected from the group consisting of a primary amine, a secondary amine, a tertiary amine, and a quaternary ammonium; and [d] a polyanion, and measuring a substance formed or consumed in the reaction.

Abstract: A method of easily measuring whether or not an LXR ligand has the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration in a mammal by using the binding activity between LXR and a coactivator, and a method of identifying LXR ligands that do not have the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration by using the binding activity between LXR and a coactivator.

Abstract: A method of analyzing vitamin E components in a lipoproteinby subjecting a lipoprotein-containing sample to ion exchange chromatography to separate the lipoprotein, reacting the separated lipoprotein to a pretreating solution containing an organic solvent and a surfactant to liberate vitamin E components, and then subjecting the liberated vitamin E components to reverse phase chromatography. Also described is a method of judging various pathological conditions such as the pathological conditions of diabetes, the risks of coronary artery diseases, and the pathological conditions of myocardial infarction using levels of vitamin E components in the lipoprotein as an index.

Abstract: It is intended to provide a compound inhibiting the activity of a protein having an amino acid sequence which is the same or substantially the same as one of the amino acid sequences represented by SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and so on, or its salt; a compound inhibiting the expression of a gene of the above protein; an antisense nucleotide containing a base sequence which is complementary or substantially complementary to the base sequence of a DNA encoding the above protein or its partial peptide or a part of the base sequence; an antibody against the above protein or its partial peptide; and so on. The above compound, antisense nucleotide, antibody and so on are usable as a prophylactic/therapeutic agent for respiratory diseases, etc.

Abstract: Disclosed is a method for reducing measurement errors due to inhibition of catalase by azide in a method for quantification of a component to be measured, in which hydrogen peroxide derived from a component other than the component to be measured is decomposed by a catalase. The method for reducing measurement errors due to inhibition of catalase by azide employs a catalase which has a subunit having a molecular mass of 75 kDa or higher and is derived from a microorganism, when hydrogen peroxide derived from a component other than the component to be measured is decomposed by the catalase followed by quantification of hydrogen peroxide derived from the component to be measured to quantify the component to be measured.

Abstract: A test strip or electrochemical sensor for measuring the amount of an analyte in a biological fluid, e.g. the glucose content of whole blood, includes a size self-limiting reagent formulation employing an enzyme system for reaction with the analyte, the reactive system mixed into a water-soluble swellable polymer matrix containing small water-insoluble particles having a nominal size of about 0.05 to 20 ?m, preferably about 1 to 10 ?m. The weight ratio of the water-insoluble particles to the water-soluble swellable polymer matrix is about 1/2 to 2/1. The reagent formulation is deposited onto a non-porous substrate to form a thin layer about 6-16 ?m thick, providing a rapid and stable response to application of a sample, while being insensitive to the amount of the sample.

Abstract: Assays methods for clinical evaluation of conditions that might be treated with copper antagonists. These conditions include diabetes and other glucose metabolism disorders, lipid disorders, neurological disorders, and heart disease. The assays utilize a correlation between copper levels and one or more of the markers hemoglobin AIc and extracellular superoxide dismutase activity, in order to detect the condition, predict progression of the condition and assess a patient's response to copper antagonist therapy in these conditions by monitoring the level of these markers.

Abstract: A device and methods for continuous precision blood sampling from a patient with a micro impedance pump as the driver in a microfluidic system. Depending on the needs of medical technologies, the micro impedance pump in the intravascular diagnostic and therapeutic sampling system serves in a forward pumping function for blood sampling, in a backward infusing for therapeutic treatment, and in a valving function for controlling fluid flow.

Abstract: Provided herein are compositions and methods for identifying individuals at risk for developing coronary artery disease (CAD).

Abstract: A method of measuring a lipid in a specific lipoprotein characterized by using a polycyclic polyoxyalkylene derivative at least in the step of determining the specificity of the measurement of the target lipid.